GLP-1 drugs in Medicaid: the coverage gap

Weekly injections of semaglutide (Wegovy) and tirzepatide can produce 15 to 21 percent body-weight reductions in clinical trials. For the roughly 90 million Americans enrolled in Medicaid, the public insurance programme serving low-income adults and children, these results might seem like a clear case for coverage. The reality is far more fragmented.

The statutory starting point

Federal law has historically allowed states to exclude weight-loss medications from their Medicaid formularies under the Social Security Act. Obesity drugs were long grouped alongside cosmetic and non-essential treatments. That framing has slowly shifted as the FDA began classifying severe obesity as a chronic disease and as the clinical evidence for GLP-1 receptor agonists in cardiovascular risk reduction accumulated^[1]. But the statutory flexibility remains: states retain wide discretion over which drugs they cover for which indications.

What the evidence shows about state coverage

A 2024 JAMA research letter by Liu and Rome analysed formulary and preferred drug list data across 47 US states with publicly available Medicaid information. The study documented trends in antiobesity medication reimbursement from 2011 to 2022 and found coverage rates for GLP-1 class drugs to be low and highly variable across states^[1]. Coverage that did exist was commonly restricted by prior authorisation requirements, step therapy mandates (requiring failure on cheaper drugs first), and BMI thresholds stricter than the approved labelling.

A 2026 analysis in the Journal of Managed Care and Specialty Pharmacy reinforced this picture. Using 2023 pharmacy claims data across commercial, Medicare, and Medicaid populations, researchers found that GLP-1 utilisation for obesity correlated only weakly with actual obesity prevalence in Medicaid beneficiaries, suggesting coverage policy rather than clinical need is the binding constraint. States with unrestricted or restricted coverage still showed higher utilisation than states with no coverage at all.

Who bears the burden of restricted coverage

Medicaid enrols a disproportionate share of people with obesity-related comorbidities and limited incomes. A 2026 study in the International Journal of Quality in Health Care used the 2022 Medical Expenditure Panel Survey to examine semaglutide access across roughly 30 million US adults with type 2 diabetes^[2]. Individuals with above-median incomes were significantly more likely to use semaglutide (OR 1.61, 95% CI 1.14 to 2.26). Private insurance raised the odds further (OR 1.52, 95% CI 1.04 to 2.22). The authors noted that lower-income adults are "disproportionately affected by diabetes" while facing the greatest barriers to the drugs shown to treat it.

The race and ethnicity dimension compounds the picture. A 2026 study published in Obesity examined 2,060 patients at a major tertiary care centre across two time periods: January 2024, before Massachusetts Medicaid (MassHealth) expanded GLP-1 obesity coverage, and April 2024, after the expansion. In January 2024, Black and Hispanic patients were 49 percent and 47 percent less likely to be prescribed semaglutide or tirzepatide than white patients. After MassHealth expanded coverage, those racial disparities narrowed substantially. The study framed insurance coverage as "a critical determinant in equitable medication access."

The cost argument cuts both ways

States resistant to coverage frequently cite cost. Published list prices for Wegovy and Zepbound run roughly $1,300 to $1,400 per month before rebates. A 2025 study in JAMA Health Forum modelled the 10-year fiscal impact of expanding GLP-1 coverage for obesity across Medicare (a proxy analysis widely cited in Medicaid debates). The base-case projection estimated $65.9 billion in drug costs offset by $18.2 billion in downstream health care savings, yielding net increased spending of $47.7 billion over a decade^[3]. At lower uptake and adherence assumptions, net costs fell to around $8 billion over ten years.

The counterargument: obesity drives spending on cardiovascular disease, type 2 diabetes, joint replacement, and hospitalisation. Modelling that focuses only on drug costs without projecting downstream comorbidity avoidance is incomplete. No peer-reviewed model has fully resolved the long-run net fiscal question for Medicaid specifically, partly because adherence data beyond two years remains limited.

What is shifting at the federal level

On 1 July 2026, the US Centers for Medicare and Medicaid Services launched a temporary 18-month Medicare GLP-1 bridge programme covering Wegovy, Zepbound, and Foundayo for weight management under Part D. An analysis by KFF published 29 June 2026 estimated that 3.8 million Medicare beneficiaries met the eligibility criteria in 2023. The programme is Medicare-only and does not automatically change state Medicaid formularies, but it creates political and precedent pressure on states that have resisted coverage. Federal Medicaid matching funds make the calculus different from Medicare: any new mandatory coverage that raises state Medicaid spending requires states to find matching funds from their own budgets.

What to watch

The GLP-1 Medicaid coverage landscape is moving faster than the published literature can track. Readers monitoring access developments should watch for state legislative sessions, which set formulary mandates; CMS guidance on Medicaid drug coverage exclusions; and peer-reviewed modelling specific to Medicaid populations, where comorbidity burden and cost-offset dynamics differ from Medicare. For drug-level detail, the semaglutide overview and tirzepatide overview pages on this site track regulatory and coverage status across seven countries.

This article covers coverage policy and access research. It is not medical advice. Drug coverage rules vary by state and year, and eligibility criteria change. Consult a healthcare provider and verify current formulary status with your state Medicaid programme before making any treatment decisions.